Insmed
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- -
- Employees
- 912
- Market Cap
- $13.2B
- Introduction
Insmed, Inc. is a global biopharmaceutical company, which engages in the development and commercialization of therapies for patients with rare diseases. Its focuses on Brensocatib, and Treprostinil Palmitil Inhalation Powder (TPIP) pipeline. The company was founded in 1988 and is headquartered in Bridgewater, NJ.
A Study of the Efficacy and Safety of Brensocatib in Adults With Moderate to Severe Hidradenitis Suppurativa (HS)
- First Posted Date
- 2024-11-13
- Last Posted Date
- 2024-12-19
- Lead Sponsor
- Insmed Incorporated
- Target Recruit Count
- 204
- Registration Number
- NCT06685835
- Locations
- 🇺🇸
USA002, Baton Rouge, Louisiana, United States
A Study to Assess the Relative Bioavailability of Brensocatib Pediatric Oral Solution to Oral Tablets in Healthy Participants
Phase 1
Completed
- Conditions
- Interventions
- First Posted Date
- 2024-04-03
- Last Posted Date
- 2024-06-13
- Lead Sponsor
- Insmed Incorporated
- Target Recruit Count
- 24
- Registration Number
- NCT06344728
- Locations
- 🇺🇸
USA001, Dallas, Texas, United States
Single Dose Escalation Study of TR02 (Sustained Lipid Inhalation Technology [SLITâ„¢] Amikacin) in Participants With Cystic Fibrosis (CF) Having Chronic Infections of Pseudomonas Aeruginosa
- First Posted Date
- 2024-02-02
- Last Posted Date
- 2024-02-02
- Lead Sponsor
- Insmed Incorporated
- Target Recruit Count
- 18
- Registration Number
- NCT06238856
A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of C16TR for Inhalation With Tyvaso® Cohort in Healthy Participants
- First Posted Date
- 2024-01-05
- Last Posted Date
- 2024-01-05
- Lead Sponsor
- Insmed Incorporated
- Target Recruit Count
- 24
- Registration Number
- NCT06193031
- Locations
- 🇺🇸
USA001, Los Angeles, California, United States
A Study of the Palatability and Acceptability of Different Brensocatib Oral Liquid Formulations in Healthy Participants
- First Posted Date
- 2023-12-21
- Last Posted Date
- 2024-01-22
- Lead Sponsor
- Insmed Incorporated
- Target Recruit Count
- 20
- Registration Number
- NCT06178783
- Locations
- 🇺🇸
USA001, Dallas, Texas, United States
A Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Treprostinil Palmitil Inhalation Powder (TPIP) in Healthy Participants
Phase 1
Completed
- Conditions
- Interventions
- First Posted Date
- 2023-10-19
- Last Posted Date
- 2023-10-19
- Lead Sponsor
- Insmed Incorporated
- Target Recruit Count
- 42
- Registration Number
- NCT06091579
- Locations
- 🇺🇸
USA001, Austin, Texas, United States
A Study of the Efficacy and Safety of Brensocatib in Participants With Chronic Rhinosinusitis Without Nasal Polyps (CRSsNP)
Phase 2
Recruiting
- Conditions
- Interventions
- First Posted Date
- 2023-08-28
- Last Posted Date
- 2024-11-20
- Lead Sponsor
- Insmed Incorporated
- Target Recruit Count
- 270
- Registration Number
- NCT06013241
- Locations
- 🇺🇸
USA036, Chicago, Illinois, United States
🇺🇸USA003, New Albany, Indiana, United States
🇺🇸USA035, Mandeville, Louisiana, United States
A Study to Investigate Lung Deposition of Inhaled Amikacin-loaded Liposomes in Healthy Male Participants
- First Posted Date
- 2023-08-21
- Last Posted Date
- 2023-08-21
- Lead Sponsor
- Insmed Incorporated
- Target Recruit Count
- 6
- Registration Number
- NCT05999942
A Study to Investigate Effect of Clarithromycin, a Strong CYP3A4 Inhibitor, on Brensocatib Pharmacokinetics in Healthy Participants
- First Posted Date
- 2023-07-28
- Last Posted Date
- 2023-12-11
- Lead Sponsor
- Insmed Incorporated
- Target Recruit Count
- 22
- Registration Number
- NCT05965570
- Locations
- 🇺🇸
USA001, Dallas, Texas, United States
A Study of the Safety, Pharmacokinetics, and Pharmacodynamics of INS1007 in Healthy Japanese and Caucasian Participants
- First Posted Date
- 2023-07-03
- Last Posted Date
- 2023-07-03
- Lead Sponsor
- Insmed Incorporated
- Target Recruit Count
- 82
- Registration Number
- NCT05927597
- Locations
- 🇺🇸
USA001, Glendale, California, United States
© Copyright 2024. All Rights Reserved by MedPath